Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > ORGANIZATION
ORGANIZATION
- New JPMA Director General Keen to Make “Special Price Maintenance” Happen after 15 Years
June 23, 2023
- FPMAJ Makes 1st Update for Generic Supply Guidelines in 9 Years
June 22, 2023
- Patient Group Requests Early Approval of New ALS Drugs in Japan
June 22, 2023
- Astellas’ Yoshitsugu Shitaka Elected as New FIRM Chair
June 20, 2023
- Lag and Loss Blamed on Drug Pricing System, JPMA Set to Get Involved in Corrective Steps: President
June 15, 2023
- Over 70% of Pharmacies Fill “Zero” Refill Prescriptions per Month: FPMAJ Survey
June 13, 2023
- FPMAJ Demands Better Criteria for Selecting Comparator Drugs to Factor in Disease Features and Product Positioning
June 12, 2023
- PMP Company Criteria Mar Market Attractiveness, Scrap Them: FPMAJ
June 12, 2023
- Tide Has Changed, but That Doesn’t Erase Concerns: FPMAJ Drug Pricing Chief
June 12, 2023
- Regenerative Medicine Group Hails Expert Panel’s Proposal on New Pricing Method for Innovative Therapies
June 9, 2023
- JMA Renews Opposition for Health Coverage Review for Pharmaceuticals
June 8, 2023
- Pharma Hails Expert Panel Report, Looks for Govt Leadership to Execute Reforms
June 7, 2023
- Industry’s Concerns Beginning to Sink in among Policymakers: JPMA Committee Chair
June 7, 2023
- Protect Info for Off-Patent Brands Even after Market Exit: JEMA
May 29, 2023
- Eisai’s Yasushi Okada Becomes FPMAJ Chairman
May 26, 2023
- New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
- 12 Medical and Nursing Care Groups Demand Responses to Inflation, Wage Hikes
May 26, 2023
- Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
- Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
May 24, 2023
- Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
May 19, 2023
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…